Study to Evaluate Clinical Consistency of the Liquid Formulation of GSK Biologicals' HRV Vaccine [RIX 4414] and to Evaluate Liquid Formulation Compared to Lyophilised Formulation of the HRV Vaccine Administered as a Two-Dose Primary Vaccination.

Trial Profile

Study to Evaluate Clinical Consistency of the Liquid Formulation of GSK Biologicals' HRV Vaccine [RIX 4414] and to Evaluate Liquid Formulation Compared to Lyophilised Formulation of the HRV Vaccine Administered as a Two-Dose Primary Vaccination.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2016

At a glance

  • Drugs RIX 4414 (Primary)
  • Indications Rotavirus infections
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 13 Jan 2011 Results published in Vaccine.
    • 12 May 2008 Status change
    • 22 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top